Last $21.05 USD
Change Today 0.00 / 0.00%
Volume 0.0
APNHF On Other Exchanges
Symbol
Exchange
Johannesburg
OTC US
OTC US
Frankfurt
As of 8:10 PM 04/10/13 All times are local (Market data is delayed by at least 15 minutes).

aspen pharmacare holdings lt (APNHF) Snapshot

Open
$21.05
Previous Close
$21.05
Day High
$21.05
Day Low
$21.05
52 Week High
04/10/13 - $21.05
52 Week Low
08/22/12 - $16.71
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
10/8/12
P/E TM
--
Dividend
$170.15
Dividend Yield
0.84%
Current Stock Chart for ASPEN PHARMACARE HOLDINGS LT (APNHF)

Related News

No related news articles were found.

aspen pharmacare holdings lt (APNHF) Related Businessweek News

No Related Businessweek News Found

aspen pharmacare holdings lt (APNHF) Details

Aspen Pharmacare Holdings Limited manufactures, markets, and distributes pharmaceutical products. It offers branded, generic, over-the-counter (OTC), and consumer products, as well as liquids, semi-solids, eye drops, lyophilised vials, and sterile injectables in South Africa, Sub-Saharan Africa, the Asia Pacific, and internationally. The company provides gastrointestinal drugs under the Altosec, Zantac, and Coloxyl brands; respiratory therapeutics under the Avamys, Foxair, Seretide, and Chemists Own Cough Suppressant brands; endocrine products under the Eltroxin, Eutroxsig, Eutropin, and Insunorm brands; cardiovascular drugs under the Rosucrest, Cidorix, Aldomet, Aggrastat, Lanoxin, Cardivel, Clovix, and Coumadin brands; Calman and Sedopan for the treatment of nervous tension and mild depression; vitamins, herbal, and complementary products under the Hemovit, Suplan, Licovit, and Triavit brands; Sildenafil for the treatment of erectile dysfunction; and oncology drugs under the Lanvis and Purinethol brands. It also offers anti-microbial drugs under the Septrin, Aspen Meropenem, and Augmentin brands; Zyloric for the treatment of gout; Aspen Lamzid and Tribuss for the treatment of HIV/AIDS; Infacare, an infant nutritional product; Dutch medicines for assorted ailments; analgesic drugs under the Coldril, Mybulen, Stilpane, Diclopar, Herron Gold, Herron Blue, Action, and Indocid brands; Bio-Oil, a dermatological drug; ophthalmic therapeutics under the Chlorsig and Murine brands; and Imuran, an immunosuppressant drug. The company’s OTC products comprise Somnil, Hyospasmol, Ibumol and Sinuclear, as well as Flora Balance, a probiotic; and Calci-dence, a calcium supplement. It serves pharmacies, retail pharmacy chains, hospitals, clinics, prescribing specialists, dispensing general practitioners, managed healthcare funders, and retail stores in the private and public sectors. Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa.

5,210 Employees
Last Reported Date: 10/22/12

aspen pharmacare holdings lt (APNHF) Top Compensated Officers

Group Chief Executive Officer and Executive D...
Total Annual Compensation: R11.1M
Deputy Group Chief Executive, Executive Direc...
Total Annual Compensation: R9.2M
Executive Officer
Total Annual Compensation: R3.2M
Executive Officer
Total Annual Compensation: R2.2M
Compensation as of Fiscal Year 2012.

aspen pharmacare holdings lt (APNHF) Key Developments

Aspen Pharmacare Holdings Limited Reports Unaudited Group Financial Results for the Six Months Ended December 31, 2012

Aspen Pharmacare Holdings Limited reported unaudited group financial results for the six months ended December 31, 2012. Cash generated from operating activities was ZAR 1,315.8 million against ZAR 1,210.6 million a year ago. Capital expenditure on ­property, plant and equipment was ZAR 301.9 million against ZAR 237.0 million a year ago. Capital expenditure on­ intangible assets was ZAR 3,457.5 million against ZAR 381.3 million a year ago. Revenue was ZAR 8,997.1 million against ZAR 7,504.9 million a year ago. Operating profit was ZAR 2,485.3 million against ZAR 2,000.5 million a year ago. Profit before tax was ZAR 2,222.2 million against ZAR 1,729.1 million a year ago. Profit after tax from continuing operations was ZAR 1,683.5 million or 368.7 cents per diluted share against ZAR 1,346.0 million or 296.5 cents per diluted share a year ago. Profit for the period attributable to equity holders of the parent was ZAR 1,682.4 million against ZAR 1,495.3 million a year ago. Headline earnings from continuing operations was ZAR 1,690.7 million or 370.5 per diluted share against ZAR 1,377.0 million or 305.2 per diluted share a year ago. Normalised headline earnings from continuing operations were ZAR 1,729.3 million or 379.0 cents per diluted share against ZAR 1,390.4 million or 308.1 cents per diluted share a year ago.

Aspen Pharmacare Holdings Limited Provides Earnings Guidance for the Six Months Ended December 31, 2012

Aspen Pharmacare Holdings Limited provided earnings guidance for the six months ended December 31, 2012. For the period, the company expects DNHEPS from continuing operations to be 21% to 25%, headline earnings per share to be 15% to 19% and earnings per share to be 5% to 9%.

Aspen Pharmacare In Talks To Acquire Ingredient Facility In Netherlands

Aspen Pharmacare Holdings Limited is engaged in discussions with Merck & Co. Inc. to acquire an active pharmaceutical ingredient facility in Netherlands.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APNHF:US $21.05 USD 0.00

APNHF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hospira Inc $35.08 USD -0.10
Novartis AG SFr.71.25 CHF -0.20
Pfizer Inc $29.04 USD -0.07
View Industry Companies
 

Industry Analysis

APNHF

Industry Average

Valuation APNHF Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASPEN PHARMACARE HOLDINGS LT, please visit www.aspenpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.